Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982874 | 0.92 | PTGDR2 (0.62) | PTGDR2USP2ALPLALOX15KDM4E | |
| SCHEMBL21629618 | 0.89 | PTGDR2 (0.47) | PTGDR2USP2ALPLALOX15KDM4E | |
| SCHEMBL3982876 | 0.83 | PTGDR2 (0.65) | PTGDR2USP2ALPLALOX15KDM4E | |
| SCHEMBL16217687 | 0.83 | PTGDR2 (0.57) | PTGDR2USP2ALPLALOX15RBP4 | |
| SCHEMBL29798808 | 0.82 | APEX1 (0.48) | PTGDR2KDM4EHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL377171 | 0.82 | APEX1 (0.48) | PTGDR2KDM4EHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL25261611 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPTHTTGAA | |
| SCHEMBL394551 | 0.81 | RBP4 (0.46) | PTGDR2KDM4EHSD17B10HPGDRBP4 | |
| SCHEMBL23388820 | 0.80 | ALDH1A1 (0.50) | ALOX15KDM4EHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL29750502 | 0.80 | ALDH1A1 (0.50) | ALOX15KDM4EHSD17B10HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3691638-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240368198-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240109922-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11248010-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3440057-B1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210061823-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3691638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10662207-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109922-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | PTGDR2 2306/4885USP2 2654/4885ALPL 4652/4885 |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, ATP5ME | PTGDR2 3603/4885USP2 702/4885ALPL 4675/4885 |
| US-20240368198-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | PTGDR2 2306/4885USP2 2654/4885ALPL 4652/4885 |
| US-11248010-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | PTGDR2 2306/4885USP2 2654/4885ALPL 4652/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PTGDR2 2134/4885USP2 2773/4885ALPL 4794/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PTGDR2 2134/4885USP2 2773/4885ALPL 4794/4885 |
| US-20210061823-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | PTGDR2 2306/4885USP2 2654/4885ALPL 4652/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | PTGDR2 1831/4885USP2 2831/4885ALPL 4811/4885 |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1A | PTGDR2 2378/4885USP2 3061/4885ALPL 4688/4885 |
| US-10662207-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | PTGDR2 2306/4885USP2 2654/4885ALPL 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.